Figure 1 (Cotempla Xr Odt 1)
Cotempla Xr-odt Tablet, Orally Disintegrating
Product Images NDC 70165-200
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Cotempla Xr-odt (NDC 70165-200). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Neos Therapeutics Brands, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Figure 2 (Cotempla Xr Odt 2)
This appears to be a chart or graph showing the mean d-Methylphenidate plasma concentration over time (in hours) for two different drugs - Cotempla XR-ODT 225.9 mg and Methylphenidate Hydrochloride Extended Release Capsules 60mg. The y-axis measures the plasma concentration in ng/mL.*
Figure 3 (Cotempla Xr Odt 3)
Principal Display Panel (8.6 mg Tablet Blister Pack Carton)
This is a description of a medication named CotemplaXR-ODT, which contains Methylphenidate Extended-Release 8 6 in orally disintegrating tablets. The package contains 30 tablets with each tablet containing 8.6 mg of methylphenidate. The pharmacist is advised to dispense the enclosed medication guide to each patient. The medication should not be crushed or chewed before use. The contains a lot of garbled text that is not relevant to this medication.*
Principal Display Panel (17.3 mg Tablet Blister Pack Carton)
This is a description of a medication named Cotempla XR-ODT™. It is in the form of orally disintegrating tablets that contain methylphenidate, an extended-release medicine used to treat ADHD. The tablets must not be crushed or chewed. Each tablet contains 17.3 mg of methylphenidate, which is equal to a 20 mg strength methylphenidate hydrochloride product. The medication guide enclosed with the tablets must be dispensed to each patient. The manufacturing company's name is Neos Therapeutics. The text also includes dosage instructions and storage guidelines.*
Principal Display Panel (25.9 mg Tablet Blister Pack Carton)
This is a description of a medication called CotemplaXR-ODT, which is an orally disintegrating tablet containing Methylphenidate Extended-Release. The medication contains a medication guide that must be provided to each patient. The tablets must not be chewed or crushed and each tablet has 25.9 mg of methylphenidate. The medication comes in a pack of 30 tablets containing five blister cards. The medication is manufactured by Neos Therapeutics Brands LLC. The rest of the text includes lot numbers, temperature conditions, and other information that is not useful.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
